The Journal of Molecular Diagnostics is a premier publication in the fields of molecular medicine and pathology, published by Elsevier Science Inc. With an impressive impact factor and recognized as a Q1 journal in both Molecular Medicine and Pathology and Forensic Medicine, this journal is dedicated to advancing the understanding and application of molecular diagnostics in clinical practice. The journal features rigorous peer-reviewed research, comprehensive reviews, and cutting-edge methodologies that highlight novel diagnostic tests and biomarkers. Researchers, professionals, and students in the biomedical sciences are invited to explore its diverse array of articles and contribute to a growing body of knowledge critical for innovation in healthcare delivery. Located in the Netherlands, the journal has secure its position among the top-tier journals with its recent Scopus ranking of 20th out of 208 in Medicine Pathology and Forensic Medicine, reflecting a strong percentile ranking of 90th. With coverage spanning from 1999 to 2024, the Journal of Molecular Diagnostics remains a vital resource for anyone committed to the future of molecular research and diagnostics.

PET Clinics, published by Elsevier Inc, is a premier academic journal focusing on the advancements and applications of Positron Emission Tomography (PET) in various medical fields. With its ISSN 1556-8598 and E-ISSN 1559-7814, the journal has established a strong reputation in the scientific community, reflected in its impressive Q1 quartile rankings in Medicine (miscellaneous), Radiation, and Radiology, Nuclear Medicine, and Imaging for 2023. The journal operates within a well-defined scope that bridges innovative research and practical clinical applications, targeting professionals, researchers, and students keen on the intersection of nuclear medicine and imaging technologies. Although not an open-access journal, PET Clinics ensures accessibility through institutional subscriptions, making valuable insights available to the academic community. With an emphasis on enhancing patient care and treatment outcomes through cutting-edge imaging techniques, this journal serves as an essential resource for those seeking to expand their knowledge and expertise in the rapidly evolving field of PET.

ENDOCRINE PATHOLOGY is a premier journal published by HUMANA PRESS INC, dedicated to advancing the understanding of endocrine disorders through innovative research and clinical practices. With an impressive impact factor and consistently ranked in the Q1 quartile across multiple categories such as Endocrinology, Diabetes and Metabolism, as well as Pathology and Forensic Medicine, this journal serves as a pivotal resource for researchers and professionals in the field. The journal covers a broad spectrum of topics related to endocrine pathology, providing insights into mechanisms, diagnostics, and therapeutics that inform both clinical and laboratory practices. Although it does not offer open access, its rigorous peer-review process ensures the dissemination of high-quality, impactful research that shapes clinical strategies and enhances patient care. With distribution spanning from its inception in 1990 to 2024, ENDOCRINE PATHOLOGY stands at the forefront of endocrine research, making it an essential read for anyone involved in the study and treatment of endocrine disorders.

Clinical Lung Cancer is a prestigious journal published by CIG MEDIA GROUP, LP, dedicated to advancing the field of oncology and pulmonary medicine since its establishment in 2000. With an impressive impact factor and high ranking within its fields—achieving Q1 status in Oncology and Pulmonary and Respiratory Medicine in 2023—this journal serves as a vital resource for researchers, clinicians, and students alike. Covering a wide scope of topics related to lung cancer, Clinical Lung Cancer offers a platform for innovative studies, clinical trials, and comprehensive reviews that contribute to both theory and practice. While it operates on a subscription basis, the quality of content is reflected in its ranked status within the top quartile of cancer research journals. This journal plays a critical role in shaping the future of lung cancer research and treatment, making it an essential destination for those looking to stay at the forefront of the field.

Journal of Cancer is a premier, peer-reviewed academic journal published by IVYSPRING INTERNATIONAL PUBLISHING that focuses on advancing the field of oncology. With an impact factor reflecting its significant contributions, this journal ranks in the 80th percentile of medical journals pertaining to oncology, positioning it at #79 out of 404 in Scopus. Since its inception in 2010, the journal has embraced an Open Access model, ensuring that groundbreaking research reaches a global audience without barriers. Based in Australia, the journal addresses a wide array of topics within cancer research, catering to researchers, healthcare professionals, and students committed to enhancing their understanding of the complexities of cancer. Amidst evolving challenges in oncology, the Journal of Cancer serves as a vital platform for disseminating innovative findings, fostering collaboration, and promoting informed decisions that can lead to improved cancer outcomes worldwide.

BREAST CANCER RESEARCH, published by BMC, is a prestigious open-access journal dedicated to advancing the field of oncology with a specific focus on breast cancer. Since its inception in 1999, the journal has established itself as a leading platform for disseminating high-quality research, with an impressive impact factor and recognition in the Q1 category for both Cancer Research and Oncology as of 2023. The journal is ranked 45th out of 404 in the field of Medicine _ Oncology and 37th out of 230 in Biochemistry, Genetics and Molecular Biology _ Cancer Research, placing it in the top echelons of research quality and relevance at 88th and 84th percentiles, respectively. BREAST CANCER RESEARCH is committed to facilitating rapid and open access to groundbreaking findings, making it an invaluable resource for researchers, healthcare professionals, and students striving to enhance their understanding of breast cancer mechanisms, treatments, and prevention strategies. With its base in the United Kingdom, the journal continues to foster international collaborations and discussions aimed at improving patient outcomes and enriching cancer research worldwide.

ACTA CYTOLOGICA is a premier journal dedicated to the field of cytology, offering a platform for researchers, professionals, and students interested in the intricate study of cellular biology and its applications in the medical domain. Published by KARGER in Switzerland, the journal has been a vital resource since its inception in 1960 and is recognized for its rigorous peer-reviewed articles. With a notable impact factor reflecting its significance—ranked in the Q2 category in both Medicine (miscellaneous) and Pathology and Forensic Medicine, and Q3 in Histology for 2023—ACTA CYTOLOGICA continues to contribute valuable insights into cytological research and its implications for clinical practice. The journal maintains an annual focus on cutting-edge studies and reviews that enhance understanding and methodological advancements in cytology. Although it does not provide open access, it remains an essential read for those involved in histology and pathology, promising to keep them abreast of the latest findings and technological innovations in the field.

DIAGNOSTIC CYTOPATHOLOGY is a scholarly journal dedicated to advancing the field of cytopathology through the publication of high-quality research and reviews. Founded in 1985 and published by Wiley, this journal provides vital insights into the diagnosis and management of diseases through cytological techniques. With a strong presence in the academic community, it currently holds a Q3 ranking in the fields of Histology, Medicine (miscellaneous), and Pathology and Forensic Medicine, reflecting its commitment to fostering knowledge and innovation in these areas. Researchers and clinicians alike can benefit from its comprehensive articles that delve into cutting-edge methodologies and diagnostic strategies. Although not an Open Access journal, DIAGNOSTIC CYTOPATHOLOGY remains a crucial resource for professionals seeking to enhance their understanding and practice in the diagnostic realm. With an ISSN of 8755-1039 and an E-ISSN of 1097-0339, the journal continues to publish impactful studies well into 2024, ensuring that essential advancements in cytopathology reach a global audience.

Journal of Cytology, published by Wolters Kluwer Medknow Publications, stands as a pivotal resource in the fields of cytology, histology, and pathology. With an ISSN of 0970-9371 and an E-ISSN of 0974-5165, this peer-reviewed, open-access journal has been disseminating vital research since its inception in 1985, transitioning to open access in 2008 to enhance global accessibility to its scholarly articles. Operating from its base in Mumbai, India, the journal is categorized in the Q3 quartile for histology and pathology according to the 2023 rankings, affirming its ongoing contribution to the scientific community. Researchers and professionals can benefit from a wide array of cutting-edge studies and reviews that advance the understanding of cytological practices. The journal's commitment to disseminating high-impact research is reflected in its Scopus rankings, positioning it among the significant players in its field. By facilitating open access, the Journal of Cytology aims to foster knowledge exchange and inspire new investigations among scholars, clinicians, and students alike.

The Journal of Cancer Research and Therapeutics is a prominent peer-reviewed platform dedicated to advancing scientific knowledge in the fields of oncology, radiology, and therapeutic interventions. Published by Wolters Kluwer Medknow Publications in India, this journal has been an essential resource for researchers and professionals since its inception in 2005, with a convergence of findings through to 2024. Although classified within the Q3 quartile across multiple relevant categories in the 2023 rankings, the journal maintains a significant impact in the fields of medicine, particularly in oncology and radiology, as evidenced by its Scopus rankings. The journal aims to disseminate high-quality research, case studies, and clinical trials that contribute to understanding and improving cancer treatments and patient care. With its accessibility to a global audience, the Journal of Cancer Research and Therapeutics plays a pivotal role in fostering dialogue and collaboration among researchers and healthcare professionals dedicated to combating cancer.